Related Experiment Videos
Inhibitors of phospholipid intracellular signaling as antiproliferative agents
Abstract:
The improved understanding of oncogenesis and the involvement of oncogenes and tumor suppressor genes, has led to a rational approach of specific target-directed anti-cancer drug development. Cancer genes have been found to be important not only in the control of cell proliferation but also in the mediation of processes such as drug resistance, metastasis, neo-vascularization (angiogenesis), and apoptosis. These are all important targets in their own right and the development of drugs against specific "upstream" targets in oncogenic or growth factor signal transduction cascades it may be possible to inhibit multiple "downstream" targets. Ultimately, to test the hypothesis that signaling pathways offer good targets for anticancer drug development will take several years of careful clinical study and we cannot say at this time whether the approach will work. There are a small number of compounds in the early stages of clinical development as anticancer agents that may act by inhibiting growth factor signaling pathways. In all cases the activity of the compounds on intracellular signaling pathways was discovered after their identification as antiproliferative agents. There are also compounds in preclinical development that have been specifically developed as inhibitors of growth factor signaling, although their selectivity for tumor cells compared to normal tissue remains to be investigated fully in appropriate animal tumor models. It is possible that a single antisignaling drug by itself may not have the power to completely inhibit tumor growth and a combination of drugs may be needed. It may also take a combination of drugs to prevent the emergence of resistance. Clearly there are several challenges to developing this new class of anticancer drugs, and there will undoubtedly be others that must be faced.
Insights
Targeted anti-cancer drugs are being developed by understanding oncogenesis. Inhibiting growth factor signaling pathways shows promise for cancer treatment, but requires further clinical study and may necessitate combination therapies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Improved understanding of oncogenesis, oncogenes, and tumor suppressor genes drives rational anti-cancer drug development.
- Cancer genes regulate cell proliferation, drug resistance, metastasis, angiogenesis, and apoptosis, presenting multiple therapeutic targets.
- Targeting "upstream" signaling pathways may inhibit multiple "downstream" targets simultaneously.
Purpose of the Study:
- To evaluate the potential of targeting signaling pathways for anti-cancer drug development.
- To explore the efficacy of novel anti-cancer agents that inhibit growth factor signaling.
Main Methods:
- Review of compounds in early clinical and preclinical development targeting growth factor signaling pathways.
- Analysis of the discovery process for anti-proliferative compounds acting on intracellular signaling.
- Assessment of the need for combination therapies and challenges in developing anti-signaling drugs.
Main Results:
- Several compounds targeting growth factor signaling are in early clinical development, identified initially by their anti-proliferative effects.
- Preclinical compounds specifically designed as growth factor signaling inhibitors require further investigation into tumor cell selectivity.
- The hypothesis that signaling pathways are good anti-cancer targets requires extensive clinical validation.
Conclusions:
- Targeting oncogenic and growth factor signaling pathways represents a rational approach to anti-cancer drug development.
- Clinical studies are necessary to confirm the efficacy of anti-signaling drugs.
- Combination therapies may be essential for complete tumor inhibition and overcoming drug resistance.